key: cord-1029272-uqk6bwxj authors: Pairo-Castineira, E.; Rawlik, K.; Klaric, L.; Law, A.; Clohisey Hendry, S.; Baillie, J. K. title: GWAS and meta-analysis identifies multiple new genetic mechanisms underlying severe Covid-19. date: 2022-03-07 journal: nan DOI: 10.1101/2022.03.07.22271833 sha: 6582cf0fe642bbe4b8e48cc80b8135e5974b8cc1 doc_id: 1029272 cord_uid: uqk6bwxj Pulmonary inflammation drives critical illness in Covid-19, creating a clinically homogeneous extreme phenotype, which we have previously shown to be highly efficient for discovery of genetic associations. Despite the advanced stage of illness, we have found that immunomodulatory therapies have strong beneficial effects in this group. Further genetic discoveries may identify additional therapeutic targets to modulate severe disease. In this new data release from the GenOMICC (Genetics Of Mortality in Critical Care) study we include new microarray genotyping data from additional critically-ill cases in the UK and Brazil, together with cohorts of severe Covid-19 from the ISARIC4C and SCOURGE studies, and meta-analysis with previously-reported data. We find an additional numconvincingnew new genetic associations. Many are in potentially druggable targets, in inflammatory signalling (JAK1, PDE4A), monocyte-macrophage differentiation (CSF2), immunometabolism (SLC2A5, AK5), and host factors required for viral entry and replication (TMPRSS2, RAB2A). As with our previous work, these results provide tractable therapeutic targets for modulation of harmful host-mediated inflammation in Covid-19. Critical illness in Covid-19 is a relatively narrow clinical phenotype characterised by hypoxaemic respiratory failure 9 in which lung injury is, at least in part, caused by host-mediated inflammation. 1;2 The international GenOMICC (Genetics of Mortality in Critical Care) consortium has shown that critical illness is a highly efficient phenotype for discovery of genetic variants associated with Covid-19, 3;4 contributing the largest signal to recent meta-analyses 10 despite only including a relatively small number of patients. This is consistent with our previous predictions for other respiratory viral illnesses. 11;12 New discoveries in the first GenOMICC study (implicating OAS1, TYK2, IFNAR2, and DPP9), 3 completed only 5 months after the first patient presented to a participating intensive care unit, led to new understanding of the host:pathogen interaction, 3;13;14 and, in part, led to the discovery of a new effective treatment for severe Covid-19. 15 Here, we provide an updated analysis of the international GenOMICC study comprising a combination of microarray genotype data from 11,325 critically ill cases in the UK (9,279 cases) and Brazil (2, 186) , combined with other studies recruiting hospitalised patients with a strong focus on severe and critical disease: ISARIC4C (655 cases) and SCOURGE consortium (5,934 cases)( Table 1) . We put these new results in context by completing a meta-analysis of the new GenOMICC GWAS results with previously-published data. The design of the GenOMICC study has been previously described. 3;4 Briefly, patients with confirmed Covid-19 requiring continuous cardiorespiratory monitoring or organ support (a generalisable definition for admission to a critical care area) were recruited in 2020-21. Using participants recruited and genotyped in GenOMICC and ISARIC4C since the first reported GenOMICC GWAS, 3 we performed ancestry-specific GWAS largely following the methods we previously described 3;4 (see Material and Methods, and Supplementary Material). Using the results of these GWAS, previously reported results obtained using GenOMICC participants with whole genome sequencing data 4 , and data from GenOMICC Brazil, we performed trans-ancestry and -platform meta analyses, within the GenOMICC study, for a critically ill Covid-19 phenotype and a hospitalised Covid-19 phenotype (see Material and Methods). Results of these GenOMICC-only meta analyses are illustrated in the lower parts of Figure 1 and Supplementary Figure 3 for the critically ill and hospitalised phenotypes respectively. 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . In order to put these new findings in the context of existing knowledge, we performed comprehensive meta analyses, drawing on further GWAS results for the two phenotypes of interest, including data kindly shared by the SCOURGE consortium and published data from the the Covid-19 Human Genetics Initiative (HGIv6, 2021). Characteristics of contributing studies to the meta analyses are summarised in Table 1 and Supplementary Table 1 for the critically ill and hospitalised phenotypes, with further details on each study provided in the Supplementary Material. Since leave-one-out analyses from the HGIv6 release were not available, we used a mathematical subtraction approach, as in our previous work, 4 ,to remove the GenOMICC signals from HGIv6, yielding an independent data set. This was essential because previous GenOMICC data contribute 20 to 50% of each genetic association signal in the HGI analyses. The results of these All Critical Cohorts and All Hospitalised Cohorts meta analyses are illustrated in Figure 1 and Supplementary Figure 3 . Independent lead variants for the critically ill phenotype are summarised in Table 2 with more details provided in Supplementary Table 2, while Supplementary Table 4 contains details of lead variants from the analysis of the hospitalised phenotype. Since no replication cohorts are available for these meta-analysis, we use heterogeneity across studies to assess the reliability of individual findings (see Supplementary Table 2 and 4). Due to the unusually extreme phenotype in the GenOMICC study, there is heterogeneity detected for the strongest associations from our previous work when compared to studies with more permissive inclusion criteria. Importantly, significant heterogeneity is not detected for the new findings we report here(Supplementary Table 2 Table 1 : Description of cohorts included in the critical meta-analysis with median age and percentage of females for the cases. NA: information not available for this cohort. * mean was provided rather than the median. ** data was available for the hospitalisation cohort but not for the critically-ill patients. In order to infer the effect of genetically-determined variation in gene expression on disease susceptibility, we performed a TWAS for the critical ill phenotype using gene expression data (GTExv8 21 ) for two disease-relevant tissues, lung and whole blood. We found significant associations with P < 1 × 10 −6 between critical Covid-19 and predicted expression in lung (25) , blood (18) and all-tissue meta-analysis (90; Supplementary file TWAS.xlsx) In this latest analysis of the GenOMICC study of critical Covid-19, building on the foundations of previously published data from our group and others, we report a total of 45 genetic associations with severe Covid-19, of which 14 have not been reported previously (Table 2) . After conditional analysis we find two extra secondary signals in known loci (see details in Materials and methods). In this brief report we provide a superficial description of selected findings. Our results are provided in full in Supplementary Tables 2 & 4 . We find a strong association in a key intracellular signalling kinase, JAK1, which is stimulated by numerous cytokines including Type I interferons and IL-6. Along with TYK2, which we previously reported to be associated with severe Covid-19, 3 JAK1 is the target for JAK inhibitors, which have recently been shown to be effective therapeutics in Covid-19. 15 Although the direction of effect is not clear from our genetic data for either gene, the therapeutic signal is consistent across multiple trials, providing proof-of-concept for target identification using genetics in critical illness. We report a new lead variant within CSF2, the gene encoding granulocyte-macrophage colony stimulating factor (GM-CSF), a key cytokine in production and differentiation of myeloid cells including monocytes, macrophages and neutrophils. We previously reported that circulating levels of GM-CSF are associated with severe disease, 22 supporting a role for therapeutic targeting in severe Covid. In addition, we show that low expression of PDE4A is associated with critical Covid-19. This phosphodiesterase regulates production of multiple inflammatory cytokines by myeloid cells and is targeted by several existing drugs for treatment of a range of inflammatory diseases. 23;24 Multiple genes implicated in viral entry are associated with severe disease. In addition to ACE2, 19 we see for the first time a genome-wide significant association in TMPRSS2, a key host protease which facilitates viral entry, which we have previously studied as a candidate gene. 25 This effect may be lineage-specific. 26 A strong GWAS association is seen in RAB2A (Table 2) , with TWAS evidence more expression of this gene is associated with worse disease (Table 3 ). This gene is highly ranked in our previous MAIC 27 meta-analysis of host genes implicated in SARS-CoV-2 interaction using in vitro and clinical data, 28 and is consistent with CRISPR screen evidence showing that RAB2A is required for viral replication. 29 TWAS provides a broad assessment of the effect on illness severity of genotype-predicted expression of specific transcripts in relevant tissues. TWAS results suggest a range of strongly-plausible genes, with direction of effect for gene expression effects in lung, whole blood and cross-tissue metaTWAS ( Table 3 , Supplemental file twas.xlsx). These include intriguing opposing effect estimates for predicted expression of various chemokine receptors (CCR1, CCR2, CCR9 vs CCR3 and CCR5) interferonα subtypes (IFNA10 vs IFNA8) and intercellular adhesion molecules (ICAM1 vs ICAM3, ICAM5). Caution is needed in interpretation of these expression effects since the molecular mechanism underlying association is not known. Although our focus on critical illness enhances discovery power, it has the disadvantage of combining genetic signals for multiple stages in disease progression including viral exposure, infection and replication, and development of inflammatory lung disease. From these data alone we cannot identify when in disease progression, or where in the body, the causal effect happens. Because we performed a meta-analysis of multiple studies which may have slightly different definitions of the phenotype, effect sizes differ between studies. This, together with ancestry-specific effects, 3 may explain heterogeneity in strong GWAS signals, such as the LZTFL1 signal in table 2. Different studies also have sets of variants which are not completely overlapping, causing P-values between variants in high LD to be more different than expected. Although most of the studies contain individuals from multiple ancestries, a large majority of the individuals are from European ancestry. In future work, there is a scientific and moral imperative to include the full diversity of human populations. Together, these results deepen our understanding of disease pathogenesis and highlights new biological mechanisms of disease, some of which have the potential for therapeutic targeting. 4 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 5 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 : Selected TWAS results for lung, whole blood and metaTWAS with Z > 5 in any analysis and P meta < 1×10 −5 (See Supplementary File twas.xlsx for full results). Gene: Gene symbol, Z lung : TWAS Z-score in lung, Z blood : TWAS Z-score in blood, Z meta : metaTWAS mean Z-score, Z SD : metaTWAS Z-score standard deviation, n meta : number of SNPs included in metaTWAS, P meta : metaTWAS Pvalue. 6 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The critically ill Covid-19 group included patients who were hospitalized owing to symptoms associated with laboratory-confirmed SARS-CoV-2 infection and who required respiratory support or whose cause of death was associated with Covid-19 In the critical analysis we included GenOMICC, critically-ill patients from ISARIC4C, HGIv6 phenothype A2 with subraction of GenOMICC data, SCOURGE severity grades 3 and 4 vs population controls, and 23andme respiratory support phenotype. Summary description of each analysis can be found in Supplementary material and a table with the included studies can be found in table 1. All meta-analysis across studies were performed using an inverse-variance weighting method and control for population stratification in the METAL software 30 We used plink 1.9 to clump variants that were genome-wide significant for each analysis with P 1 = 5 × 10 −8 , P 2 = 0.01, clump distance 1500Kb and r 2 = 0.1. As a reference population for clumping we used individuals from European ancestry with whole genome sequence available in the GenOMICC study and whole genomes from 100K Genomics England project 4 . We performed a step-wise conditional analysis to find independent signals. In the hospitalised analysis we performed an European-specific meta-analysis to find conditionally independent signals. For the 8 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 7, 2022. ; https://doi.org/10.1101/2022.03.07.22271833 doi: medRxiv preprint critical illness meta-analysis European-specific data is not available, but European ancestry is largely predominant (87.2% of critically-ill cases) and we performed the conditional analysis using the metaanalysis results of the whole cohort . To perform the conditional analysis we used GCTA 1.9.3 -cojo-slct function 32 . The parameters for the function were pval = 5 × 10 −8 , a distance of 10,000 kb and a colinear threshold of 0.9 33 , and the reference population for the conditional analysis were individuals from European ancestry with whole genome sequence available in the GenOMICC study and whole genomes from 100K Genomics England project 4 . We performed TWAS in the MetaXcan framework and the GTExv8 eQTL and sQTL MASHR-M models available for download in http://predictdb.org/. We first calculated individual TWAS for whole blood and lung with the S-PrediXcan function 34;35 . Then we performed a metaTWAS including data from all tissues to increase statistical power using s-MultiXcan 36 . We applied Bonferroni correction to the results in order to choose significant genes and introns for each analysis. Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Tissue-specific Immunopathology in Fatal COVID-19 Genetic mechanisms of critical illness in covid-19 Whole genome sequencing reveals host factors underlying critical Covid-19 Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial Targeting the host immune response to fight infection Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study & on Covid-19 (scourge), S. C. t. U. R. o. h. G. A genome-wide association study of COVID-19 related hospitalization in Spain reveals genetic disparities among sexes Features of 20 133 uk patients in hospital with covid-19 using the isaric who clinical characterisation protocol: prospective observational cohort study Mapping the human genetic architecture of covid-19 The Role of Host Genetics in Susceptibility to Influenza: A Systematic Review The role of host genetic factors in respiratory tract infectious diseases: Systematic review, meta-analyses and field synopsis A neanderthal oas1 isoform protects individuals of european ancestry against covid-19 susceptibility and severity A prenylated dsrna sensor protects against severe covid-19 Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis Whole genome sequencing identifies multiple loci for critical illness caused by covid-19. medRxiv Mapping the human genetic architecture of COVID-19 Genomewide association study of severe covid-19 with respiratory failure Mapping the human genetic architecture of COVID-19: An update New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations The GTEx Consortium atlas of genetic regulatory effects across human tissues Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19 Phosphodiesterase 4 inhibitors in immunemediated diseases: Mode of action, clinical applications, current and future perspectives Selective inhibition of phosphodiesterases 4A, b, c and d isoforms in chronic respiratory diseases: Current and future evidences A common TMPRSS2 variant has a protective effect against severe COVID-19 Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19 Functional interrogation of a sars-cov-2 host protein interactome identifies unique and shared coronavirus host factors. bioRxiv : the preprint server for biology METAL: fast and efficient meta-analysis of genomewide association scans Mapping identifiers for the integration of genomic datasets with the r/bioconductor package biomart Gcta: a tool for genome-wide complex trait analysis Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics A gene-based association method for mapping traits using reference transcriptome data Integrating predicted transcriptome from multiple tissues improves association detection We thank the patients and their loved ones who volunteered to contribute to this study at one of the most difficult times in their lives, and the research staff in every intensive care unit who recruited patients at personal risk during the most extreme conditions ever witnessed in most hospitals. GenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome Trust Senior Research Fellowship (J.K We would like to thank the research participants and employees of 23andMe for making this work possible. A full list of contributors who have provided data that was collated in the HGI project, including previous iterations, is available at https://www.covid19hg.org/acknowledgements.